Search results
Results from the WOW.Com Content Network
The first list was published in 1977 and included 208 medications. [8] [2] [9] The WHO updates the list every two years. [10] There are 306 medications in the 14th list in 2005, [11] 410 in the 19th list in 2015, [10] 433 in the 20th list in 2017, [12] [13] 460 in the 21st list in 2019, [14] [15] [16] and 479 in the 22nd list in 2021.
2023 was a strong year for innovative new drugs, with new medications for Alzheimer’s disease, weight loss, ... The FDA is expected to make a decision about the drug in early 2024.
In 2024, the United States suffered from an "all-time high" scarcity of over three hundred different kinds of drugs and medications in healthcare and pharmacy settings, surpassing the number of drug shortages present in 2014. Drugs and medications impacted by the shortage included asthma medications, anesthesia and analgesic medications ...
Drug Trade name Type Main indications Company Sales (USD millions/year) ∆ vs 2014 1 Adalimumab: Humira Biologic Rheumatoid arthritis: AbbVie Inc. 14,012 1,469 2 Ledipasvir/sofosbuvir: Harvoni Small molecule Hepatitis C: Gilead Sciences: 13,864 11,737 3 Etanercept: Enbrel Biologic Rheumatoid arthritis: Amgen. Pfizer. 8,697 4,009 4 Infliximab ...
Year of discovery Name of the drug Year when the synthesis mechanism was developed Year that was Patented Governmental approval Patented expiry Drug type * 2000: Bevacizumab: 2004: 2024 MA 2001: Valdecoxib: 2016: N/A SM 2001: Etoricoxib: 2016: N/A SM 2003: Alirocumab: 2015: 2035 MA 2006: Linagliptin: 2011 [31] 2031 SM 2007: Apixaban: 2012: 2032 ...
COVID-19. Pfizer. 3C-like protease inhibitor (Nirmatrelvir) / inhibition of metabolism of nirmatrelvir (ritonavir) Nevirapine. HIV. non- nucleoside reverse transcriptase inhibitor. Nitazoxanide. Broad-spectrum antiviral.
One analysis found people using bisphosphonates were 15% less likely to die than nonusers after a 2.8 year follow up. Metformin Metformin, which has been around for 60 years, is the most ...
October 29, 2024 at 7:52 AM. Novartis Q3 Earnings Beats Expectations On Strong Sales From Key Drugs, Lifts 2024 Outlook. On Tuesday, Novartis AG (NYSE: NVS) reported third-quarter sales of $12.823 ...